Abbott (ABT) to Sell Abbott Medical Optics to Johnson & Johnson (JNJ) in $4.33B Deal
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
"We've been actively and strategically shaping our portfolio, which has recently focused on developing leadership positions in cardiovascular devices and expanding diagnostics," said Miles D. White, chairman and chief executive officer, Abbott. "Our vision care business will be well-positioned for continued success and advancement with Johnson & Johnson, and I'd like to thank our employees for building a successful business."
Abbott's vision business has products in areas including cataract surgery, laser vision correction (LASIK) and corneal care products (contact solution, eye drops, etc.).
The net impact of this transaction is not expected to impact Abbott's overall targeted ongoing earnings per share in 2017. This targeted earnings per share excludes the expected gain on this transaction and any costs related to the transaction. The transaction is expected to close in the first quarter of 2017 and is subject to customary closing conditions, including regulatory approvals.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ExxonMobil (XOM) Tops Q3 EPS by 5c; CapEx Light of Views
- AbbVie (ABBV) Tops Q3 EPS by 1c; Boosts FY16 EPS Outlook
- Zimmer Biomet Holdings (ZBH) Announces Acquisition of RespondWell
Create E-mail Alert Related CategoriesCorporate News, Hot Corp. News, Hot M&A, Management Comments, Mergers and Acquisitions
Related EntitiesTwitter, Earnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!